Sotagliflozin exhibits metabolic benefits in diabetes with metabolic syndrome
A new meta-analysis revealed that sotagliflozin has metabolic benefits like BP-lowering and weight loss and is a sensible remedial choice for treating diabetes with a metabolic disorder. The analysis results were published in the Journal of Diabetes and Its Complications.
In recent years, diabetes, a global pandemic, has significantly increased the global burden of cardiovascular and renal diseases. Metabolic syndrome, such as weight gain, insulin resistance, dyslipidemia, and hypertension, are frequently associated with type 2 diabetes (T2D). Sotagliflozin is a novel first-in-class dual SGLT-1/2 inhibitor, with good glucose control, cardiorenal benefits, and a good safety profile. Previous studies have not completely analyzed Sotagliflozin from its metabolic advantages point of view, so researchers conducted a meta-analysis on the metabolic effects of a dual sodium-glucose co-transporter-1/2 inhibitor, sotagliflozin, on blood pressure (BP) and body weight in people with diabetes.
Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, an electronic search was carried out from inception up to March 8, 2022, to determine eligible randomized-controlled trials of sotagliflozin-reporting BP and weight change outcomes in adults with diabetes. 1766 records were identified, 1129 studies were screened and finally, 16 studies with 19,140 participants met the inclusion criteria and were included.
Results
Compared with the placebo, sotagliflozin had a mean systolic blood pressure reduction, mean diastolic blood pressure reduction, and mean weight loss.
weighted mean differences (WMDs) | 95 % CI | |
mean systolic blood pressure reduction | −2.60 mmHg | −2.90 to −2.30 |
mean diastolic blood pressure reduction | -0.96 mmHg | −1.17 to −0.75 |
mean weight loss | −1.88 kg | −2.16 to −1.59 |
Metabolic effects on BP-lowering and weight loss were observed across diabetes status, duration of follow-up, and chronic kidney disease comorbidity.
Sotagliflozin had significant effects on people with type 1 diabetes and also showed a dose-response relationship between BP-lowering and weight loss.
TAKE-HOME MESSAGE:
This meta-analysis of 16 trials assessed the metabolic effects of sotagliflozin, a dual SGLT1/2 inhibitor, on blood pressure and body weight in patients with diabetes. Sotagliflozin therapy was associated with a mean systolic blood pressure reduction of −2.6 mm Hg, a mean diastolic blood pressure reduction of −0.96 mm Hg, and a mean weight loss of −1.88 kg compared with placebo. The effects were consistent across diabetes status, duration of follow-up, and comorbid status (specifically CKD). Metabolic effects were also noted in patients with type 1 diabetes.
Sotagliflozin is a reasonable option for the management of diabetes with metabolic syndrome.
For further reading:
Wu J, Zhao X, Chen H, Zhu S. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials [published online ahead of print, 2022 Nov 4]. J Diabetes Complications. 2022;36(12):108352. doi: 10.1016/j.jdiacomp.2022.108352
